...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

"Does this mean less chance of a buyout in the next 6-12 months or more? Does this increase or lesson the chances of getting listed on some exchange?

OR is it more likely we sit on our shares/coin/dead money for another 3-5 years?"

Fuzzy, yes. There is no other way to read this. Today's news did not even prop up RVX. 

 

Koo

Share
New Message
Please login to post a reply